Current Report Filing (8-k)
June 15 2020 - 5:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 15, 2020
Hancock
Jaffe Laboratories, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38325
|
|
33-0936180
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
70
Doppler
Irvine,
California 92618
(Address
of principal executive offices) (Zip Code)
(949)
261-2900
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.00001 per share
|
|
HJLI
|
|
The
NASDAQ Stock Market LLC
|
Warrant
to Purchase Common Stock
|
|
HJLIW
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
8.01 Other Events
On
June 15, 2020, Hancock Jaffe Laboratories, Inc. (the “Company”) announced that it received on June
8 formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the
“Panel”) had determined to grant the Company’s request for continued listing on The Nasdaq Capital Market, pursuant
to an extension through July 31, 2020, to evidence compliance with the minimum $2.5 million stockholders’ equity requirement
set forth in Nasdaq Listing Rule 5550(b). The Company is taking definitive steps to timely evidence compliance with the terms
of the Panel’s decision; however, there can be no assurance that it will be able to do so by July 31, 2020, or that the
Panel will grant a further extension if required, notwithstanding the fact that the Panel has the discretion to grant an extension
through October 12, 2020, pursuant to the Nasdaq Listing Rules.
As
previously disclosed, on April 14, 2020, the Company received written notice from the Nasdaq Listing Qualifications Staff (the
“Staff”) indicating that, due to the Company’s continued non-compliance with Nasdaq Listing Rule 5550(b), the
Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing before
the Panel. The Panel’s decision dated June 8, 2020 follows the Company’s hearing before the Panel, at which the Company
requested continued listing pursuant to an extension through July 31, 2020, to evidence full compliance with the stockholders’
equity requirement and its continued compliance with all other applicable requirements for continued listing on Nasdaq.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HANCOCK
JAFFE LABORATORIES, INC.
|
|
|
Dated:
June 15, 2020
|
/s/
Robert A. Berman
|
|
Robert
A. Berman
|
|
Chief
Executive Officer
|
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Apr 2023 to Apr 2024